Adlai Nortye (ANL), a promising player in the pharmaceutical industry, has officially entered the stock market arena. The company's Initial Public Offering (IPO) took off at a solid $18 per
Explore Adlai Nortye, a global biopharmaceutical innovator in clinical-stage development, crafting unique and advanced immuno-oncology medicines.